Business Wire

Seoul Semiconductor’s SunLike Series Natural Spectrum LEDs Adopted by German Lighting Brand WALTRON for Aquarium Lighting

29.10.2019 20:08:00 EET | Business Wire | Press release

Share

Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED products and technology, announced that WALTRON, specialists in LED lighting systems for aquariums and terrariums based in Lower Saxony, Germany, has adopted Seoul Semiconductor’s SunLike Series natural spectrum LEDs for daytime® Pendix, WALTRON’s aquarium lighting solutions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191029005896/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Seoul Semiconductor’s SunLike Series natural spectrum LEDs for aquarium lighting of German brand WALTRON (Photo: Business Wire)

Indoor aquariums are full of colorful corals, fish, and water plants living in an ecosystem similar to nature. Direct sunlight is typically avoided in these spaces in order to limit the reproduction of algae. This is necessary to keep water from becoming turbid and harming the ecological balance of the aquarium system. As a result, lighting solutions play an important role in maintaining growth without disturbing the ecological cycle.

The daytime Pendix is a matrix LED module with 9 different color temperatures and features a customized spectral lighting design that closely matches the spectrum of natural sunlight enabled by SunLike Series LEDs. Different light colors such as white, blue, and red can be combined in the module to provide the optimal lighting solution for both saltwater aquariums and freshwater aquariums.

Sunlight has always played an important role with plant growth in nature. SunLike Series natural spectrum LEDs are similar to sunlight which radiate a uniform amount of energy at all wavelengths, including infrared and ultraviolet as the optimal light source for plant growth. The technology lowers the light peaks of red, green and blue to be more similar to sunlight’s spectral curve in order to provide a better growth formula than what is common in conventional LEDs. This results in a more natural and healthy environment for fish, plants, and corals while further decreasing algae growth on glass.

Light sources with SunLike Series LEDs more accurately show the color of objects as they would appear in natural sunlight. Optimized to natural light spectra and color rendering of CRI-97 (close to CRI-100 of sunlight), and higher than the CRI-80 of conventional LEDs, SunLike Series LEDs deliver more significant benefits in vivid color, contrast detail, and quality of light consistency. These qualities can be vital to aquariums, enabling the owners to more accurately observe and attend to the overall growth and health status of fish.

“We are pleased to expand this aquarium LED lighting portfolio. Our SunLike Series natural spectrum LEDs as healthy light sources will offer the considerable benefits for better growth of fishes and plants in aquarium, compared to conventional LEDs,” said Carlo Romiti, Europe sales Vice President of Seoul Semiconductor. “Seoul Semiconductor will continue to support the needs of customers with a range of innovative LED lighting solutions.”

Seoul Semiconductor developed SunLike Series natural spectrum LEDs in collaboration with Toshiba Materials’ TRI-R spectrum technology in 2017 as the first LED light source to closely match the spectrum of natural sunlight.

To learn more about daytime Pendix by WALTRON, please visit:
http://daytime.de/led-systeme-pendix

To learn more about the SunLike Series natural spectrum LEDs, please visit: http://www.seoulsemicon.com/en/technology/Sunlike/

# # #

About WALTRON
WALTRON specializes in innovative LED lighting systems that highlight the natural beauty of animals and plants in aquariums and terrariums brilliantly. Its daytime® brand delivers lighting solutions for the demanding aquarium owner. We invite you to discover the many possibilities of the daytime® product lines: matrix, eco, cluster and cluster control. For more information, please visit http://daytime.de/.

About Seoul Semiconductor
Seoul Semiconductor develops and commercializes LEDs for automotive, general illumination, specialty lighting, and backlighting markets. As the second-largest LED manufacturer globally excluding the captive market, Seoul Semiconductor holds more than 14,000 patents, offers a wide range of technologies, and mass produces innovative LED products such as SunLike – delivering the world’s best light quality in a next-generation LED enabling human-centric lighting optimized for circadian rhythms; WICOP – a simpler structured package-free LED which provides market leading color uniformity and cost savings at the fixture level, providing high lumen density and design flexibility; NanoDriver Series – the world’s smallest 24W DC LED drivers; Acrich, the world's first high-voltage AC-driven LED technology developed in 2005, including all AC LED-related technologies from chip to module and circuit fabrication, and nPola, a new LED product based on GaN-substrate technology that achieves more than ten times the output of conventional LEDs. UCD constitutes a high color gamut display which delivers more than 90% NTSC. For more information, please visit www.seoulsemicon.com/en.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Seoul Semiconductor Inc.
Jeonghee Kim
Tel: +82-70-4391-8311
Email: jeonghee.kim@seoulsemicon.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye